AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

How we improved the treatment of Hodgkin lymphoma

Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy.

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.

October 18, 2024

Vol.50 No.39

By McKenzie Prillaman

Clinical Roundup

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Positive results from the NIAGARA phase III trial showed Imfinzi (durvalumab)in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

Updated results from the HIMALAYA phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

September 20, 2024

Vol.50 No.35

Guest Editorial

From clinician scientist to nonprofit CEO

I was a practicing pediatric hematologist oncologist and researcher for 21 years. As a doctor, it was a tremendous privilege to be invited into the lives of patients and families dealing with blood cancers and be entrusted with their care. As a researcher, it was incredibly rewarding to help bring more effective blood cancer therapies to kids.

Monjuvi improves PFS in r/r follicular lymphoma in phase III trial

Incyte announced positive topline results from the phase III inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide (Revlimid) and rituximab (Rituxan) compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma.

September 06, 2024

Vol.50 No.33

AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

YOU MAY BE INTERESTED IN

How we improved the treatment of Hodgkin lymphoma

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

From clinician scientist to nonprofit CEO

Monjuvi improves PFS in r/r follicular lymphoma in phase III trial

Renew today!

Subscriber content

Never miss an issue!

Login

AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

YOU MAY BE INTERESTED IN

How we improved the treatment of Hodgkin lymphoma

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

From clinician scientist to nonprofit CEO

Monjuvi improves PFS in r/r follicular lymphoma in phase III trial

Never miss an issue!

Login

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo